Noninvasive real-time monitoring by alamarBlue(®) during in vitro culture of three-dimensional tissue-engineered bone constructs
- PMID: 23327780
- PMCID: PMC3719443
- DOI: 10.1089/ten.TEC.2012.0601
Noninvasive real-time monitoring by alamarBlue(®) during in vitro culture of three-dimensional tissue-engineered bone constructs
Abstract
Bone tissue engineering (TE) aims to develop reproducible and predictive three-dimensional (3D) TE constructs, defined as cell-seeded scaffolds produced by a controlled in vitro process, to heal or replace damaged and nonfunctional bone. To control and assure the quality of the bone TE constructs, a prerequisite for regulatory authorization, there is a need to develop noninvasive analysis techniques to evaluate TE constructs and to monitor their behavior in real time during in vitro culturing. Most analysis techniques, however, are limited to destructive end-point analyses. This study investigates the use of the nontoxic alamarBlue(®) (AB) reagent, which is an indicator for metabolic cell activity, for monitoring the cellularity of 3D TE constructs in vitro as part of a bioreactor culturing processes. Within the field of TE, bioreactors have a huge potential in the translation of TE concepts to the clinic. Hence, the use of the AB reagent was evaluated not only in static cultures, but also in dynamic cultures in a perfusion bioreactor setup. Hereto, the AB assay was successfully integrated in the bioreactor-driven TE construct culture process in a noninvasive way. The obtained results indicate a linear correlation between the overall metabolic activity and the total DNA content of a scaffold upon seeding as well as during the initial stages of cell proliferation. This makes the AB reagent a powerful tool to follow-up bone TE constructs in real-time during static as well as dynamic 3D cultures. Hence, the AB reagent can be successfully used to monitor and predict cell confluence in a growing 3D TE construct.
Figures






Similar articles
-
Three-dimensional characterization of tissue-engineered constructs by contrast-enhanced nanofocus computed tomography.Tissue Eng Part C Methods. 2014 Mar;20(3):177-87. doi: 10.1089/ten.TEC.2013.0041. Epub 2013 Oct 19. Tissue Eng Part C Methods. 2014. PMID: 23800097 Free PMC article.
-
A perfusion bioreactor for engineering bone constructs: an in vitro and in vivo study.Tissue Eng Part C Methods. 2011 May;17(5):505-16. doi: 10.1089/ten.TEC.2010.0468. Epub 2011 Feb 17. Tissue Eng Part C Methods. 2011. PMID: 21171934
-
Essential design considerations for the resazurin reduction assay to noninvasively quantify cell expansion within perfused extracellular matrix scaffolds.Biomaterials. 2017 Jun;129:163-175. doi: 10.1016/j.biomaterials.2017.02.015. Epub 2017 Feb 16. Biomaterials. 2017. PMID: 28343003 Free PMC article.
-
Bioreactor systems for bone tissue engineering.Tissue Eng Part B Rev. 2011 Aug;17(4):263-80. doi: 10.1089/ten.TEB.2010.0612. Epub 2011 Jun 10. Tissue Eng Part B Rev. 2011. PMID: 21495897 Review.
-
Modulation of cell differentiation in bone tissue engineering constructs cultured in a bioreactor.Adv Exp Med Biol. 2006;585:225-41. doi: 10.1007/978-0-387-34133-0_16. Adv Exp Med Biol. 2006. PMID: 17120788 Review.
Cited by
-
3D Bioprinted Bacteriostatic Hyperelastic Bone Scaffold for Damage-Specific Bone Regeneration.Polymers (Basel). 2021 Mar 30;13(7):1099. doi: 10.3390/polym13071099. Polymers (Basel). 2021. PMID: 33808295 Free PMC article.
-
Integrated approach to cell growth and recovery in silk fibroin scaffolds via a spin-down system.Biomater Biosyst. 2025 Aug 11;19:100118. doi: 10.1016/j.bbiosy.2025.100118. eCollection 2025 Sep. Biomater Biosyst. 2025. PMID: 40837884 Free PMC article.
-
Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro.Sci Rep. 2017 Mar 3;7:43519. doi: 10.1038/srep43519. Sci Rep. 2017. PMID: 28256634 Free PMC article.
-
Ex vivo non-invasive assessment of cell viability and proliferation in bio-engineered whole organ constructs.Biomaterials. 2015 Jun;52:103-12. doi: 10.1016/j.biomaterials.2015.01.061. Epub 2015 Feb 21. Biomaterials. 2015. PMID: 25818417 Free PMC article.
-
Computational Modeling of Human Mesenchymal Stromal Cell Proliferation and Extra-Cellular Matrix Production in 3D Porous Scaffolds in a Perfusion Bioreactor: The Effect of Growth Factors.Front Bioeng Biotechnol. 2020 Apr 29;8:376. doi: 10.3389/fbioe.2020.00376. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32411692 Free PMC article.
References
-
- Schneider C.K. Salmikangas P. Jilma B. Flamion B. Todorova L.R. Paphitou A., et al. Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery. 2010;9:195. - PubMed
-
- European Medicines Agency. Guideline on Human Cell-Based Medicinal Products. 2007. EMEA/CHMP/410869/2006.
-
- European Medicines Agency. EMEA/724428/2009. Assement report for ChondroCelect. Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins. 2009. Procedure No. EMEA/H/C/000878.
-
- Salter E. Goh B. Hung B. Hutton D. Ghone N. Grayson W.L. Bone tissue engineering bioreactors: a role in the clinic? Tissue Eng Part B Rev. 2012;18:62. - PubMed
-
- Rauh J. Milan F. Gunther K.P. Stiehler M. Bioreactor systems for bone tissue engineering. Tissue Eng Part B Rev. 2011;17:263. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources